Tonix Pharmaceuticals Holding Corp.

NasdaqGS:TNXP Stock Report

Market Cap: US$180.9m

Tonix Pharmaceuticals Holding Management

Management criteria checks 2/4

Tonix Pharmaceuticals Holding's CEO is Seth Lederman, appointed in Oct 2011, has a tenure of 14.67 years. total yearly compensation is $3.17M, comprised of 22.2% salary and 77.8% bonuses, including company stock and options. directly owns 0.18% of the company’s shares, worth $329.23K. The average tenure of the management team and the board of directors is 3.9 years and 7.5 years respectively.

Key information

Seth Lederman

Chief executive officer

US$3.2m

Total compensation

CEO salary percentage22.15%
CEO tenure14.7yrs
CEO ownership0.2%
Management average tenure3.9yrs
Board average tenure7.5yrs

Recent management updates

Recent updates

Seeking Alpha • Mar 17

Tonix Q4: Revenue Beat, EPS Miss, Early Signs Of Tonmya Momentum

Summary Tonix Pharmaceuticals reported Q4 GAAP EPS of -$3.98 (miss), but revenue surged 109% YoY to $5.39M, beating consensus by $2.42M. Early Tonmya launch metrics show promising initial uptake, with 4,200 prescriptions and 1,500+ prescribers, but revenue conversion remains uncertain due to pending insurance coverage. Operating expenses hit $138.8M in FY25, driving a net loss of $124M, though cash reserves doubled to $207.6M, supporting operations into Q1 2027. TNXP trades at a negative enterprise value, reflecting skepticism about Tonmya's commercial ramp and future cash flows; I maintain a cautious hold rating pending clearer prescription growth. Read the full article on Seeking Alpha
Analysis Article • Dec 01

Will Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Aug 14

Here's Why We're Not Too Worried About Tonix Pharmaceuticals Holding's (NASDAQ:TNXP) Cash Burn Situation

NasdaqCM:TNXP 1 Year Share Price vs Fair Value Explore Tonix Pharmaceuticals Holding's Fair Values from the Community...

CEO Compensation Analysis

How has Seth Lederman's remuneration changed compared to Tonix Pharmaceuticals Holding's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$147m

Dec 31 2025US$3mUS$702k

-US$124m

Sep 30 2025n/an/a

-US$99m

Jun 30 2025n/an/a

-US$81m

Mar 31 2025n/an/a

-US$132m

Dec 31 2024US$2mUS$675k

-US$130m

Sep 30 2024n/an/a

-US$135m

Jun 30 2024n/an/a

-US$149m

Mar 31 2024n/an/a

-US$99m

Dec 31 2023US$2mUS$675k

-US$117m

Sep 30 2023n/an/a

-US$123m

Jun 30 2023n/an/a

-US$124m

Mar 31 2023n/an/a

-US$123m

Dec 31 2022US$5mUS$675k

-US$117m

Sep 30 2022n/an/a

-US$112m

Jun 30 2022n/an/a

-US$102m

Mar 31 2022n/an/a

-US$98m

Dec 31 2021US$8mUS$675k

-US$92m

Sep 30 2021n/an/a

-US$80m

Jun 30 2021n/an/a

-US$73m

Mar 31 2021n/an/a

-US$64m

Dec 31 2020US$4mUS$614k

-US$52m

Sep 30 2020n/an/a

-US$46m

Jun 30 2020n/an/a

-US$42m

Mar 31 2020n/an/a

-US$34m

Dec 31 2019US$1mUS$585k

-US$31m

Compensation vs Market: Seth's total compensation ($USD3.17M) is above average for companies of similar size in the US market ($USD1.66M).

Compensation vs Earnings: Seth's compensation has increased whilst the company is unprofitable.

CEO

Seth Lederman (68 yo)

14.7yrs
Tenure
US$3,168,830
Compensation

Dr. Seth Lederman, M. D., is a Co-Founder of Tonix Pharmaceuticals Holding Corp. (formerly, Krele Pharmaceuticals) and has been its Chairman, Chief Executive Officer and President since October 7, 2011. Dr...

Leadership Team

NamePositionTenureCompensationOwnership
Seth Lederman
Co-Founder14.7yrsUS$3.17m0.18%
$ 329.2k
Bradley Saenger
CFO & Treasurer10.3yrsUS$1.14m0.0044%
$ 8.0k
Jessica Morris
Chief Operating Officer10.3yrsUS$1.23m0%
$ 0
Gregory Sullivan
Chief Medical Officer & Secretary9.3yrsUS$1.22m0%
$ 0
Siobhan Fogarty
Chief Technical Officer1.3yrsno data0%
$ 0
Irina Ishak
General Counselless than a yearno datano data
Darryl Rideout
Executive Vice President of Experimental Chemistry6.4yrsno datano data
Sina Bavari
Executive Vice President of Infectious Disease Research & Development3.9yrsno datano data
Zeil Rosenberg
Executive Vice President of Medical3.4yrsno datano data
Thomas Englese
Executive Vice President of Commercial Operations1.8yrsno datano data
Ganesh Kamath
Head of Market Accessless than a yearno datano data
3.9yrs
Average Tenure
57yo
Average Age

Experienced Management: TNXP's management team is considered experienced (3.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Seth Lederman
Co-Founder14.7yrsUS$3.17m0.18%
$ 329.2k
Adeoye Olukotun
Independent Director7.8yrsUS$243.83k0%
$ 0
R. Stillwell
Independent Director3.3yrsUS$243.83k0.031%
$ 56.8k
David Grange
Independent Director8.3yrsUS$243.83k0%
$ 0
Margaret Bell
Independent Director8.8yrsUS$243.83k0%
$ 0
Richard Bagger
Independent Director6yrsUS$243.83k0%
$ 0
James Hunter
Director1yrUS$280.21k0%
$ 0
Iredell Iglehart
Member of Scientific Advisory Boardno datano datano data
James Treco
Independent Lead Director7.3yrsUS$263.83k0.0016%
$ 2.8k
Harvey Moldofsky
Member of Scientific Advisory Board15yrsno datano data
Carolyn Taylor
Independent Director4.9yrsUS$243.83k0.0026%
$ 4.7k
7.5yrs
Average Tenure
69yo
Average Age

Experienced Board: TNXP's board of directors are considered experienced (7.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/14 21:43
End of Day Share Price 2026/06/12 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tonix Pharmaceuticals Holding Corp. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Chiara RussoBrean Capital Historical (Janney Montgomery)
David BuckB. Riley Securities, Inc.